ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
amd_paper.pdf (600 kB)

Amodiaquine as COVID-19 Mpro Inhibitor: A Theoretical Study

preprint
submitted on 24.06.2020, 13:09 and posted on 26.06.2020, 12:45 by BN Acharya

COVID-19 is caused by severe respiratory syndrome –coronavirus 2 (SARS CoV-2). This has been declared as a global pandemic by World Health Organization (WHO). Currently only supportive care is available for treatment of patients. However availability of direct therapeutic approaches would greatly benefit the patient care and reduce death among COVID- 19 patients. Repurposing of approved drugs against COVID-19 would be a faster method to identify direct therapeutics against COVID-19. This study describes screening and identification of Amodiaquine a known antimalarial as COVID-19 Mpro inhibitor by pharmacophore modeling and molecular docking. Amodiaquine may be repurposed as COVID-19 drug after thorough clinical tests.

Funding

None

History

Email Address of Submitting Author

bnacharya@yahoo.com

Institution

Defence Research and Development Establishment

Country

India

ORCID For Submitting Author

0000-0003-4946-5311

Declaration of Conflict of Interest

None

Exports

Logo branding

Exports